Jiangsu (SH:688426)2026-01-29 07:50Financial Performance - Jiangsu Kangwei Century Biotechnology Co., Ltd. expects a net profit attributable to shareholders of the parent company to range from -111.76 million to -91.44 million yuan, representing a year-on-year reduction in losses of 28.91% to 41.83%[2] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to be between -143.30 million and -122.98 million yuan, reflecting a year-on-year reduction in losses of 20.64% to 31.90%[2] - The previous year's net profit attributable to shareholders of the parent company was -157.21 million yuan, with a total profit of -164.70 million yuan[3] Business Growth - The main reason for the reduced losses is the significant increase in overall sales revenue, primarily driven by rapid growth in the company's technology service businesses, including gene sequencing and gene synthesis[4] - The company is currently in a recovery phase within the life sciences and diagnostic reagents industry, and new business expansions have not yet achieved economies of scale[4] Forecast and Risks - The earnings forecast is based on preliminary calculations by the company's finance department and has not yet been audited by certified public accountants[5] - Investors are advised to pay attention to investment risks as the forecast data is preliminary and the final financial data will be disclosed in the official 2025 annual report[6]